USE OF THE COMPLEX BETWEEN PROSTATE SPECIFIC ANTIGEN AND α1-PROTEASE INHIBITOR FOR SCREENING PROSTATE CANCER

This publication has 19 references indexed in Scilit:

• Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network
  Urology, 2000
• European randomized study of prostate cancer screening: first-year results of the Finnish trial
  British Journal of Cancer, 1999
• Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease
  JAMA, 1998
• The European Randomized Study of Screening for Prostate Cancer (ERSPC)
  British Journal of Urology, 1997
• Usefulness of the ratio free/total prostatespecific antigen in addition to total PSA levels in prostate cancer screening
  Urology, 1996
• Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening
  Published by American Medical Association (AMA) ,1995
• Serum Prostate Specific Antigen Complexed toα1-Antichymotrypsin as an Indicator of Prostate Cancer
  Journal of Urology, 1993
• Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin
  Clinical Chemistry, 1991
• Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
  New England Journal of Medicine, 1991
• The meaning and use of the area under a receiver operating characteristic (ROC) curve.
  Radiology, 1982